Today: Today, New England Research & Management Inc. Increases Stake in Johnson & Johnson (JNJ)

Today, New England Research & Management Inc. Increases Stake in Johnson & Johnson (JNJ)

New England Research & Management Inc. raised its stake in Johnson & Johnson (NYSE:JNJ) by 20.0% during the third quarter, Holdings Channel reports. The institutional investor owned 30,343 shares of the company’s stock after buying an additional 5,063 shares during the period. Johnson & Johnson comprises about 3.0% of New England Research & Management Inc.’s investment portfolio, making the stock its 2nd largest position. New England Research & Management Inc.’s holdings in Johnson & Johnson were worth $3,584,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in JNJ. Americafirst Capital Management LLC acquired a new stake in Johnson & Johnson during the second quarter valued at about $101,000. Tuttle Tactical Management LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at $103,000. Lenox Wealth Management Inc. increased its position in shares of Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock valued at $118,000 after buying an additional 190 shares during the period. Thomas J. Herzfeld Advisors Inc. increased its position in shares of Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock valued at $122,000 after buying an additional 690 shares during the period. Finally, NCM Capital Management Group Inc. purchased a new position in shares of Johnson & Johnson during the second quarter valued at $127,000. Institutional investors own 65.19% of the company’s stock.

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.94% during trading on Friday, reaching $114.13. 3,433,340 shares of the company were exchanged. The stock has a market capitalization of $310.49 billion, a P/E ratio of 20.03 and a beta of 0.75. Johnson & Johnson has a 52-week low of $94.28 and a 52-week high of $126.07. The stock has a 50-day moving average of $116.14 and a 200 day moving average of $118.35.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 18th. The company reported $1.68 EPS for the quarter, beating the Zacks’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The firm earned $17.80 billion during the quarter, compared to analysts’ expectations of $17.71 billion. During the same quarter last year, the firm posted $1.49 earnings per share. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post $6.72 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be paid a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 2.80%. The ex-dividend date of this dividend is Friday, November 18th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.29. Johnson & Johnson’s dividend payout ratio (DPR) is 56.64%.

JNJ has been the subject of several analyst reports. Leerink Swann restated a “buy” rating on shares of Johnson & Johnson in a research note on Sunday, September 11th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a research note on Tuesday, September 13th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 target price for the company in a research note on Monday, August 22nd. Deutsche Bank AG restated a “buy” rating and issued a $142.00 target price on shares of Johnson & Johnson in a research note on Friday, August 19th. Finally, Argus restated a “buy” rating and issued a $145.00 target price on shares of Johnson & Johnson in a research note on Friday, October 21st. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $120.79.

In other news, Director Charles Prince acquired 875 shares of Johnson & Johnson stock in a transaction on Friday, October 21st. The stock was purchased at an average price of $114.11 per share, with a total value of $99,846.25. Following the completion of the purchase, the director now owns 26,520 shares of the company’s stock, valued at approximately $3,026,197.20. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.11% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Related posts

Leave a Comment